Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer
Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer
复制标题
DOI：
10.1182/blood.v99.11.4234
复制
发表时间：
2002-06-01
期刊：
影响因子：
20.3
通讯作者：
Corradini, P
中科院分区：
文献类型：
--
作者：
Bregni, M;Dodero, A;Corradini, P
在6例乳腺癌患者和7例肾细胞癌患者中，研究了硫替帕、氟达拉滨和环磷酰胺等非清髓性条件下同种异体干细胞移植的可行性和毒性。该项目包括对无肿瘤反应和无移植物抗宿主病（GVHD）的患者使用递增剂量的供体淋巴细胞输注（DLI）和/或干扰素α (ifn α)。由于年龄、晚期和既往治疗，患者存在移植相关死亡率（TRM）的高风险。我们观察到4例肾癌和2例乳腺癌患者（1例在骨髓分子水平）在环孢素停药或DLI和/或ifn - α治疗后出现部分缓解。所有反应均伴有急性GVHD的发生。我们得出结论，低强度的同种异体干细胞移植是治疗肾癌和乳腺癌的一种可行的方法，并且利用DLI后的移植物抗肿瘤效应是一个有希望的发现。(C) 2002年由美国血液病学会出版。
The feasibility and toxicity of allogeneic stem cell transplantation after nonmyeloablative conditioning including thiotepa, fludarabine, and cyclophosphamide have been investigated in 6 patients with breast cancer and 7 patients with renal cell cancer. The program included the use of escalating doses of donor lymphocyte infusions (DLI) and/or interferon alpha (IFNalpha) for patients showing no tumor response and no graft-versus-host disease (GVHD). Patients were at high risk of transplant-related mortality (TRM) because of age, advanced stage, and previous treatments. We observed a partial remission in 4 renal cancer and in 2 breast cancer patients (one at the molecular level in the bone marrow), occurring after cyclosporine withdrawal or after DLI and/or IFNalpha. All the responses were accompanied by the occurrence of acute GVHD. We conclude that reduced-intensity allogeneic stem cell transplantation Is a feasible procedure In renal and breast cancer, and that the exploitation of graft-versus-tumor effect after DLI is a promising finding. (C) 2002 by The American Society of Hematology.